[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:her2-mutation":3},{"name":4,"total":5,"recruiting":5,"trials":6},"ERBB2 Gene",23,[7,15,21,28,35,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06043817","First-In-Human Study of STX-721\u002FPFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.021992Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07012031","Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation",[11],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.418568Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT05673928","A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)",[25],"Phase 2","2026-08-26T02:16:48.735701Z","2026-05-05T02:43:28.183681Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[32],"Phase 3","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.120702Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":40,"content_modified":41},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[39],"Phase 1","2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.992106Z",{"nct_id":43,"title":44,"phases":45,"status":12,"updated_at":46,"content_modified":47},"NCT07195695","Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment",[32],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:27.661184Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":52,"content_modified":53},"NCT07428044","A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer",[25],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:27.588648Z",{"nct_id":55,"title":56,"phases":57,"status":12,"updated_at":58,"content_modified":59},"NCT06521554","A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)",[39],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:26.963151Z",{"nct_id":61,"title":62,"phases":63,"status":12,"updated_at":64,"content_modified":65},"NCT06616766","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946",[11],"2026-08-26T02:18:15.214990Z","2026-05-05T02:35:31.680026Z",{"nct_id":67,"title":68,"phases":69,"status":12,"updated_at":70,"content_modified":71},"NCT06706076","A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and\u002For HER2 Mutations",[11],"2026-08-26T02:19:02.550788Z","2026-05-05T02:35:31.637829Z",{"nct_id":73,"title":74,"phases":75,"status":12,"updated_at":76,"content_modified":77},"NCT06581432","Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations",[25],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.144755Z",{"nct_id":79,"title":80,"phases":81,"status":12,"updated_at":82,"content_modified":83},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[11],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":85,"title":86,"phases":87,"status":12,"updated_at":88,"content_modified":89},"NCT05315700","Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",[11],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.704037Z",{"nct_id":91,"title":92,"phases":93,"status":12,"updated_at":94,"content_modified":95},"NCT07361562","A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",[39],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.101090Z",{"nct_id":97,"title":98,"phases":99,"status":12,"updated_at":100,"content_modified":101},"NCT06795009","Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer",[39],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.984599Z",{"nct_id":103,"title":104,"phases":105,"status":12,"updated_at":106,"content_modified":107},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[39],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":109,"title":110,"phases":111,"status":12,"updated_at":112,"content_modified":113},"NCT05872295","IKS014 in Advanced Solid Tumors That Express HER2",[39],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.816198Z",{"nct_id":115,"title":116,"phases":117,"status":12,"updated_at":118,"content_modified":119},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[11],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":121,"title":122,"phases":123,"status":12,"updated_at":124,"content_modified":125},"NCT06760819","A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",[25],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:26.692781Z",{"nct_id":127,"title":128,"phases":129,"status":12,"updated_at":130,"content_modified":131},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[39],"2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":133,"title":134,"phases":135,"status":12,"updated_at":136,"content_modified":137},"NCT05765851","A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors",[39],"2026-08-26T02:15:50.539717Z","2026-06-14T18:39:22.235878Z",{"nct_id":139,"title":140,"phases":141,"status":12,"updated_at":142,"content_modified":143},"NCT05099172","First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and\u002For Human Epidermal Growth Factor Receptor 2 (HER2)",[11],"2026-08-26T02:19:28.327680Z","2026-06-14T18:39:22.231084Z",{"nct_id":145,"title":146,"phases":147,"status":12,"updated_at":148,"content_modified":149},"NCT05236114","GEMINI-NSCLC: NSCLC Biomarker Study",[],"2026-08-26T02:17:44.240289Z","2026-05-13T02:55:06.297367Z"]